Table 5.

Random effects model Bayesian network meta-analysis of ORR estimation between different treatment regimens OR (A: ORR^#1; B: ORR^#2).

(A) ORR#1
Endo	3.26 (1.13, 10.17)	2.81 (1.08, 8.18)		7.37 (1.81, 33.72)
0.31 (0.1, 0.89)	Her2-tki+Endo	0.86 (0.3, 2.65)		2.24 (0.64, 8.24)
0.36 (0.12, 0.92)	1.17 (0.38, 3.34)	Her2-mAb+Endo		2.63 (0.71, 9.42)
0.14 (0.03, 0.55)	0.45 (0.12, 1.55)	0.38 (0.11, 1.4)		Her2-mAb+Her2-tki+Endo
(B) ORR#2
Her2-mAb+Chem	0.7 (0.25, 1.88)		0.97 (0.36, 2.59)
1.44 (0.53, 3.98)	Her2-mAb+CDK4/6+Endo		1.38 (0.58, 3.41)
1.03 (0.39, 2.82)	0.72 (0.29, 1.72)		Her2-mAb+CDK4/6

Note: The OR and 95%CrI for ORR between treatment regimens are shown in the table above, with the lower left corner representing each column treatment group compared to each row treatment group and the opposite in the upper right corner. OR > 1 indicates that the column treatment regimen improved the ORR of patients compared to the row treatment regimen; OR < 1 indicates that the column treatment regimen had a poorer benefit on ORR than the row treatment regimen. Significant differences between the two groups are shown in bold. (ORR: objective response rate; OR: odds ratio; CrI: credible interval).